论文部分内容阅读
近十年来抗胸腺细胞球蛋白(Antithymocyte—globulin简称ATG)已应用于临床,治疗严重型再生障碍性贫血(简称SAA),并取得了令人鼓舞的进展,一般报告有效率达40～50％,从而使SAA患者的预后有了明显改善。本文就ATG治疗SAA有关问题综述如下: 一、SAA发病的免疫学机理
In recent ten years, Antithymocyte globulin (ATG) has been used clinically in the treatment of severe aplastic anemia (SAA) and has made encouraging progress. The general reported rate of 40-50% , So that the prognosis of patients with SAA has been significantly improved. This article on the treatment of SAA ATG related issues are summarized as follows: First, the pathogenesis of SAA immunological mechanism